En | De
Sie sind hier: Onkologie » Respirationstrakt 02. Dezember 2020
Erweiterte Suche
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Endokrine Organe
Gynäkologische Tumoren
Urologische Tumoren
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 5572  vorhergehende Seite nächste Seite
   Artikel 1 - 20 / 111426  
Multicentre randomised phase II study of the perioperative administration of flurbiprofen axetil in patients with non-small cell lung cancer: study protocol of the FLAX Study.
BMJ Open
Sakamaki K, Watanabe K, Woo T, Masuda M.
PMID: 33257489 [PubMed - in process]

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
Arch Med Res
Baburaj G, Thomas L, Rao M.
PMID: 33257051 [PubMed - as supplied by publisher]

The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Technol Cancer Res Treat
Tian WJ, Liu SS, Li BR.
PMID: 33256552 [PubMed - in process]

In Silico and In Vitro Analysis of lncRNA XIST Reveals a Panel of Possible Lung Cancer Regulators and a Five-Gene Diagnostic Signature.
Cancers (Basel)
Katopodis P, Dong Q, Halai H, Fratila CI, Polychronis A, Anikin V, Sisu C, Karteris E.
PMID: 33255394 [PubMed]

Management guidelines for stage III non-small cell lung cancer.
Crit Rev Oncol Hematol
Jazieh AR, Zeitouni M, Alghamdi M, Alrujaib M, Lotfi S, Abu Daff S, Alomair A, Alshehri S, Alhusaini H, Allehebi A, Ansari J, Alnassar M, Jafar H, Alfarsi A, Abdelhafeez N, Alkattan K.
PMID: 33254035 [PubMed - as supplied by publisher]

miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer.
Transl Res
Zhong S, Golpon H, Zardo P, Borlak J.
PMID: 33253979 [PubMed - as supplied by publisher]

Qualitative emphysema and risk of COPD hospitalization in a multicenter CT lung cancer screening cohort study.
Respir Med
Gazourian L, Thedinger WB, Regis SM, Pagura EJ, Price LL, Gawlik M, Stefanescu CF, Lamb C, Rieger-Christ KM, Singh H, Casasola M, Walker AR, Rupal A, Patel AS, Come CE, Sanayei AM, Long WP, Rizzo GS, McKee AB, Washko GR, San Jose Estepar R, Wald C, McKee BJ, Thomson CC, Liesching TN.
PMID: 33253972 [PubMed - as supplied by publisher]

Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
PLoS One
Yu G, Shen Y, Xu X, Zhong F.
PMID: 33253313 [PubMed - in process]

The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers.
Mol Oncol
Kalinke L, Thakrar R, Janes SM.
PMID: 33252175 [PubMed - as supplied by publisher]

Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Technol Cancer Res Treat
Liu J, Han Y, Liu X, Wei S.
PMID: 33251978 [PubMed - in process]

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer.
Front Oncol
Rybinski B, Hosgood HD, Wiener SL, Weiser DA.
PMID: 33251146 [PubMed]

Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort.
Ann Surg Oncol
Zuo Z, Zhang G, Song P, Yang J, Li S, Zhong Z, Tan Q, Wang L, Xue Q, Gao S, Sun N, He J.
PMID: 33249521 [PubMed - as supplied by publisher]

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
Lung Cancer
Wu YL, Shi Y, Tan DSW, Xiaoqing L, Cheng Y, Zhou J, An TT, Lu Y, Zhu B, Bai C, Passos VQ, Lau YY, Xun L, Zhang L.
PMID: 33249379 [PubMed - as supplied by publisher]

The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study.
Cancer Treat Res Commun
Smit MA, Philipsen MW, Postmus PE, Putter H, Tollenaar RA, Cohen D, Mesker WE.
PMID: 33249210 [PubMed - as supplied by publisher]

Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
J Thorac Oncol
Nishio M, Yoshida T, Kumagai T, Hida T, Toyozawa R, Shimokawaji T, Goto K, Nakagawa K, Ohe Y, Seto T, Kudou K, Asato T, Zhang P, Yamamoto N.
PMID: 33248320 [PubMed - as supplied by publisher]

Immunosuppressive role of Benzo[a]pyrene in induction of lung cancer in mice.
Chem Biol Interact
Salem ML, El-Ashmawy NE, Abd El-Fattah EE, Khedr EG.
PMID: 33245929 [PubMed - as supplied by publisher]

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study.
Front Oncol
Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L.
PMID: 33244458 [PubMed]

Early diagnosis of lung cancer in people most at risk.
Br J Gen Pract
Sullivan FM, van Beusekom M.
PMID: 33243902 [PubMed - in process]

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
BMJ Open
Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, Tan C.
PMID: 33243806 [PubMed - in process]

Nurse-led, screening-triggered, early specialised palliative care intervention programme for patients with advanced lung cancer: study protocol for a multicentre randomised controlled trial.
BMJ Open
Fujisawa D, Umemura S, Okizaki A, Satomi E, Yamaguchi T, Miyaji T, Mashiko T, Kobayashi N, Kinoshita H, Mori M, Morita T, Uchitomi Y, Goto K, Ohe Y, Matsumoto Y.
PMID: 33243791 [PubMed - in process]

   Artikel 1 - 20 / 111426    Seite 1 von 5572  vorhergehende Seite nächste Seite

Rect Bottom
Adserver Footer





Haben Sie Ihr Passwort vergessen?


Neu bei My Medline?

Melden Sie sich bei My Medline an!


Mehr über My Medline erfahren

mehr >>


Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.



mehr >>


Sky right 1